Investigating heart injury in children receiving anthracycline chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on pediatric oncology patients who are about to start anthracycline chemotherapy. It aims to assess the role of echocardiography and serum biomarkers, such as NT-proBNP and cardiac Troponin-I, in predicting cardiac injury. The study recognizes the variability in patients' susceptibility to cardiotoxicity from anthracyclines and seeks to establish effective screening strategies to prevent long-term heart complications. By monitoring cardiac function before and during treatment, the study hopes to improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Paediatric oncological patients 0-18 years
* Planned start of anthracycline therapy
* Normal left ventricular systolic function according to International Guidelines before the treatment with AC

Exclusion Criteria:

* Previous anthracycline treatment, bone marrow transplantation or chest radiation
* Pre-anthracycline treatment echocardiographic evidence of:
* More than mild pericardial effusion
* More than mild mitral regurgitation
* Poor echocardiographic acoustic window

Where it's running

• IRCCS Burlo Garofolo
  Trieste, Italy, Italy Recruiting

Study contacts

• Principal investigator: Thomas Caiffa, MD — IRCCS Burlo Garofolo
• Study coordinator: Thomas Caiffa, MD
• Email: thomas.caiffa@burlo.trieste.it
• Phone: +39 0403785248

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 18F-AIPF-1026 PET/CT for MAO-A related diseases in adults

  A PET/CT test using 18F-AIPF-1026 is being looked at to see if it can help diagnose primary and metastatic lesions in adults with MAO-A–related conditions like depression, anxiety, and heart injuries.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07685860

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Heart health education with VR for breast cancer patients on certain therapies

  This trial tests a virtual reality program to help breast cancer survivors learn about heart health and healthy behaviors while they receive treatments like anthracyclines or trastuzumab.

  Recruiting at 3 sites Virginia Commonwealth University · Richmond, Virginia and 2 other locations · NCT07426913

• Using sulforaphane to protect the heart during breast cancer treatment with doxorubicin

  This study is testing if a nutritional supplement called sulforaphane can help protect the hearts of breast cancer patients receiving doxorubicin chemotherapy.

  Recruiting Phase 1/2 Texas Tech University Health Sciences Center · Lubbock, Texas · NCT03934905

• Dapagliflozin to prevent chemotherapy-related heart damage in breast cancer

  We will test if taking dapagliflozin 10 mg daily prevents heart and blood-vessel damage in adult women receiving anthracycline chemotherapy for breast cancer.

  Recruiting Phase 2 University Medical Centre Ljubljana · Ljubljana · NCT07245069

• Remote Ischemic Conditioning for Lymphoma Patients Receiving Chemotherapy

  This study is testing if a special treatment called Remote Ischemic Preconditioning can help protect the hearts of lymphoma patients from damage while they receive chemotherapy.

  Recruiting at 21 sites Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Aarhus and 23 other locations · NCT05223413

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.